Immunic Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Immunic Inc 's ROA in the second quarter of 2026?
Immunic Inc recorded a cumulative net loss of $-112 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -108.05%.

However, within the Healthcare sector 753 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4357, from total ROA ranking in the first quarter of 2026 at 5253.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	165.18 %	822.86 %	-41.13 %	-37.52 %	-29.35 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-112	-104	-97	-103	-102
Return On Assets (TTM)	-108.05 %	-133.2 %	-269.25 %	-256.4 %	-220.51 %
IMUX's Total Ranking	# 4357	# 5253	# 4656	# 4691	# 4726
Total Assets (TTM) in million	160	189	23	40	60
Seq. Total Assets Change	-15.32 %	706.43 %	-41.18 %	-33.98 %	194.68 %
Seq. Net Income Change	-	-	-	-	-

IMUX's 5 Years Annual ROA >> Back to IMUX Management Effectiveness >> Compare IMUX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 351
Sector	# 754
Overall	# 4249

Return On Assets Statistics
High	Average	Low
-36.38 %	-86.66 %	-264.95 %
(Dec 31 2020)		(Dec 31 2025)

Financial Statements
Immunic Inc 's Assets	$ 160 million	IMUX's Balance sheet
Immunic Inc 's Income	$ -34 million	Quarterly IMUX's Income Statement
IMUX's Income by Division		See IMUX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-41.13 %	-24.76 %	-58.32 %	-8.59 %	-17.13 %
Total Assets in million	23	40	53	127	139
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-97	-101	-94	-120	-93
Annual Return On Assets	-413.9 %	-252.04 %	-176.63 %	-94.69 %	-66.82 %

IMUX's 5 Years Annual ROA >> Back to IMUX Management Effectiveness >> Compare IMUX ROA to its Competitors

More Return On Assets Ratios
IMUX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IMUX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IMUX's Competitors
Subscribers only: Roa for Immunic Inc 's Suppliers
Subscribers only: Return On Assets for IMUX's Customers

You may also want to know
IMUX's Roi	IMUX's Inventory Turnover Ratio	IMUX's Growth Rates	IMUX's Dividend Comparisons
	IMUX's Profitability Ratios	IMUX's Asset Turnover Ratio	IMUX's Dividend Growth
IMUX's Roe	IMUX's Valuation Ratios	IMUX's Financial Strength Ratios	IMUX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:08:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.